Avenue Therapeutics (49Y) Stock Price & Analysis
49Y Stock Chart & Stats
- Day’s Range
- EUR 0.40 - EUR 0.40
- 52-Week Range
- EUR 0.40 - EUR 0.40
- Previous Close
- EUR 0.40
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.26M
- Enterprise Value
- -EUR 2.46M
- Total Cash (Recent Filing)
- EUR 1.94M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -0.97
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
The absence of debt reduces mandatory interest and repayment burdens, giving Avenue greater flexibility while it advances development programs. This lowers financial risk relative to a similarly loss-making company with leverage, although the benefit depends on preserving enough liquidity to fund operations.
Narrower Net Losses
The substantial reduction in annual losses indicates some progress in controlling the cost base and improving operating efficiency. If sustained, this trajectory could extend the company’s funding runway and reduce the scale of future capital needs as development activities continue.
Improved Cash Burn
Lower operating cash outflows than in earlier periods suggest better control of cash consumption, an important advantage for a development-stage biotechnology company. Continued improvement could preserve resources for clinical and regulatory work, even though operations remain cash-consuming today.
Bears Say
No Current Revenue
The complete absence of trailing revenue shows that Avenue currently lacks a recurring commercial base to support research, regulatory, and corporate spending. Without an approved product or dependable monetization stream, financial progress remains highly dependent on future development outcomes or external funding.
Persistent Cash Consumption
Negative operating and free cash flow means the business is not self-funding and must continue using available resources or seek external financing to sustain operations. This constrains strategic flexibility and leaves the company exposed if losses persist or development spending increases.
Shrinking Equity Cushion
The sharp reduction in equity reflects ongoing value erosion from operating losses and leaves a much thinner balance-sheet cushion against further setbacks. With only modest assets and continued cash consumption, Avenue has less capacity to absorb delays or fund development internally.
49Y FAQ
What was Avenue Therapeutics’s price range in the past 12 months?
What is Avenue Therapeutics’s market cap?
When is Avenue Therapeutics’s upcoming earnings report date?
How were Avenue Therapeutics’s earnings last quarter?
Is Avenue Therapeutics overvalued?
Does Avenue Therapeutics pay dividends?
What is Avenue Therapeutics’s EPS estimate?
How many shares outstanding does Avenue Therapeutics have?
What happened to Avenue Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Avenue Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Avenue Therapeutics
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Alexandra MacLean
- Employees
- 1
- Website
- www.avenuetx.com
- Address
- 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, US
Avenue Therapeutics (49Y) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 6 |
| Technical Analysis | 1 | 1 | 0 |
| Moving Averages | 3 | 3 | 6 |
